4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, heart disorder, heart failure, nutritional disorder, obesity disorder, overnutritionRecruitingPhase 32026-09-16NCT07037459
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseArterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorderActive, not recruitingPhase 32026-08-25NCT05030428
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)Heart; Heart Failure With Preserved Ejection Fraction (HFPEF)RecruitingPhase 12026-04-09NCT07219511
Safety and Efficacy of AT-001 in Patients With Diabetic CardiomyopathyDiabetes Complications, Diabetic Cardiomyopathies, Nutritional and Metabolic Diseases, cardiomyopathy, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, metabolic disease, type 2 diabetes mellitusActive, not recruitingPhase 32022-12-08NCT04083339